These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 3315285)

  • 1. Effect of L-leucine on oral melphalan kinetics in patients.
    Reece PA; Dale BM; Morris RG; Kotasek D; Gee D; Rogerson S; Sage RE
    Cancer Chemother Pharmacol; 1987; 20(3):256-8. PubMed ID: 3315285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of food on oral melphalan absorption.
    Reece PA; Kotasek D; Morris RG; Dale BM; Sage RE
    Cancer Chemother Pharmacol; 1986; 16(2):194-7. PubMed ID: 3948305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of dietary amino acids on the gastrointestinal absorption of melphalan and chlorambucil.
    Adair CG; McElnay JC
    Cancer Chemother Pharmacol; 1987; 19(4):343-6. PubMed ID: 3594717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of cimetidine with oral melphalan. A pharmacokinetic study.
    Sviland L; Robinson A; Proctor SJ; Bateman DN
    Cancer Chemother Pharmacol; 1987; 20(2):173-5. PubMed ID: 3311444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma melphalan and prednisolone concentrations during oral therapy for multiple myeloma.
    Taha IA; Ahmad RA; Gray H; Roberts CI; Rogers HJ
    Cancer Chemother Pharmacol; 1982; 9(1):57-60. PubMed ID: 7139852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral melphalan kinetics.
    Alberts DS; Chang SY; Chen HS; Evans TL; Moon TE
    Clin Pharmacol Ther; 1979 Dec; 26(6):737-45. PubMed ID: 498715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1.
    Gullbo J; Wickström M; Tullberg M; Ehrsson H; Lewensohn R; Nygren P; Luthman K; Larsson R
    J Drug Target; 2003 Jul; 11(6):355-63. PubMed ID: 14668056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of an amino acid-lowering diet on the rate of melphalan entry into brain and xenotransplanted glioma.
    Groothuis DR; Lippitz BE; Fekete I; Schlageter KE; Molnar P; Colvin OM; Roe CR; Bigner DD; Friedman HS
    Cancer Res; 1992 Oct; 52(20):5590-6. PubMed ID: 1394182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral melphalan pharmacokinetics--relation to dose in patients with multiple myeloma.
    Ehrsson H; Eksborg S; Osterborg A; Mellstedt H; Lindfors A
    Med Oncol Tumor Pharmacother; 1989; 6(2):151-4. PubMed ID: 2747308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma.
    Bosanquet AG; Gilby ED
    Cancer Chemother Pharmacol; 1984; 12(3):183-6. PubMed ID: 6705135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amino acid conferred protection against melphalan interference with melphalan therapy by L-leucine, a competitive substrate for transport.
    Vistica DT; Rabon A; Rabinovitz M
    Cancer Lett; 1979 Jan; 6(1):7-13. PubMed ID: 544013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral melphalan pharmacokinetics: influence of interferon-induced fever.
    Ehrsson H; Eksborg S; Wallin I; Osterborg A; Mellstedt H
    Clin Pharmacol Ther; 1990 Jan; 47(1):86-90. PubMed ID: 2295223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma.
    Bosanquet AG; Gilby ED
    Eur J Cancer Clin Oncol; 1982 Apr; 18(4):355-62. PubMed ID: 6889512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion.
    Choi KE; Ratain MJ; Williams SF; Golick JA; Beschorner JC; Fullem LJ; Bitran JD
    Cancer Res; 1989 Mar; 49(5):1318-21. PubMed ID: 2645050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacokinetics of melphalan during intermittent therapy of multiple myeloma.
    Loos U; Musch E; Engel M; Hartlapp JH; Hügl E; Dengler HJ
    Eur J Clin Pharmacol; 1988; 35(2):187-93. PubMed ID: 3191937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of L-alpha-amino-gamma-guanidinobutyric acid on melphalan therapy of the L1210 murine leukemia.
    Vistica DT; Rabon A; Rabinovitz M
    Cancer Lett; 1979 May; 6(6):345-50. PubMed ID: 455272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
    Pinguet F; Culine S; Bressolle F; Astre C; Serre MP; Chevillard C; Fabbro M
    Clin Cancer Res; 2000 Jan; 6(1):57-63. PubMed ID: 10656432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and phase II study of heated intraoperative intraperitoneal melphalan.
    Sugarbaker PH; Stuart OA
    Cancer Chemother Pharmacol; 2007 Feb; 59(2):151-5. PubMed ID: 17091250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetically guided dosing for intravenous melphalan: a pilot study in patients with advanced ovarian adenocarcinoma.
    Ploin DY; Tranchand B; Guastalla JP; Rebattu P; Chauvin F; Clavel M; Ardiet C
    Eur J Cancer; 1992; 28A(8-9):1311-5. PubMed ID: 1515240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of high-dose intravenous melphalan in patients undergoing peripheral blood hematopoietic progenitor-cell transplantation.
    Pinguet F; Martel P; Fabbro M; Petit I; Canal P; Culine S; Astre C; Bressolle F
    Anticancer Res; 1997; 17(1B):605-11. PubMed ID: 9066587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.